A phase I single blind clinic trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimide-activated polyethylene glycol

Haematologica

Volumn 90, Issue 4, 2005, Pages 505-515

  Björkholm, Magnus ^a   Fagrell, Bengt ^a   Przybelski, Robert ^b   Winslow, Nancy ^c   Young, Mark ^c   Winslow, Robert M ^c,d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c SANGART INC   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Blood substitutes; Clinical trials; Hemoglobin; MP4; Oxygen therapeutics; PEG

Indexed keywords

BLOOD SUBSTITUTE; HEMOGLOBIN; HEMOGLOBIN DERIVATIVE; HEMOSPAN; MACROGOL; MALEIMIDE; PENTASTAN; PLASMA SUBSTITUTE; UNCLASSIFIED DRUG;

ADULT; APPETITE DISORDER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS SPASM; HEADACHE; HEART RATE; HUMAN; HUMAN TISSUE; HYPERSENSITIVITY; HYPOXIC CELL; KIDNEY FUNCTION; LOWER ESOPHAGUS SPHINCTER; NAUSEA; OXYGEN THERAPY; OXYGEN TRANSPORT; PAIN; PHASE 1 CLINICAL TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; TOOTH PAIN; VASOCONSTRICTION; VOMITING;

ADOLESCENT; ADULT; ANOXIA; COMPLEMENT ACTIVATION; DISEASE-FREE SURVIVAL; ENZYME TESTS; FEMALE; HEMATOLOGIC TESTS; HEMODYNAMIC PROCESSES; HEMOGLOBINS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; MALE; MALEIMIDES; MIDDLE AGED; POLYETHYLENE GLYCOLS; RESPIRATORY TRANSPORT;

EID: 17844411218     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Vandegriff KD, Malavalli A, Wooldridge J, Lohman J, Winslow RM. MP4, a new non-vasoactive polyethytlene glycol-hemoglobin conjugate. Transfusion 2003;43:509-15.
2. McCarthy MR, Vandegriff KD, Winslow RM. The role of facilitated diffusion in oxygen transport by cell-free hemoglobins: implications for the design of hemoglobin-based oxygen carriers. Biophys Chem 2001;92:103-7.
3. 2 delivery by cell-free hemoglobin: a new basis for oxygen therapeutics. Am J Physiol 2003;285:H1411-H9.
4. Winslow RM, Gonzales A, Gonzales M, Magde M, McCarthy M, Rohlfs RJ, et al. Vascular resistance and the efficacy of red cell substitutes in a rat hemorrhage model. J Appl Physiol 1998;85:993-1003.
5. Drobin D, Kjellstrom B, Malm E, Malavalli A, Lohman J, Vandegriff KD, et al. Hemodynamic response and oxygen transport in pigs resuscitated with maleimide-polyethylene glycol-modified hemoglobin (MP4). J Appl Physiol 2004;96:1843-53.
6. Wettstein R, Tsai A, Erni D, Winslow R, Intagietta M. Resuscitiation with polyethylene glycol-modified human hemoglobin improves microcirculatory blood flow and tissue oxygenation after hemorrhagic shock in awake hamsters. Crit Care Med 2003;31:1824-30.
7. Acharya A, Manjula B, Smith P. Albert Einstein College of Medicine of Yeshiva University, ed. Hemoglobin crosslinkers. New York patent 1996;5:585,484.
8. Winslow RM. Current status of blood substitute research: toward a new paradigm. J Intern Med 2003;253:508-17.
9. Kerger H, Tsai AG, Saltzman DJ, Winslow RM, Intaglietta M. Fluid resuscitation with O2 vs. non-O2 carriers after 2h of hemorrhagic shock in conscious hamsters. Am J Physiol 1997;272: H525-H37.
10. Burhop KE, Estep TE. Hemoglobin-induced mypcardial lesions. Artif Cells Blood Substit Immobil Biotechnol 2001;29:101.
11. Winslow R. Hemoglobin-based red cell substitutes. Baltimore: Johns Hopkins University Press; 1992.
12. Hess J, Fadare S, Tolentino L, Bangal N, Winslow R. The intravascular persistence of crosslinked human hemoglobin. In: The Red Cell: Seventh Ann Arbor Conference. Brewer G, ed. New York: Alan R. Liss; 1989. p. 351-60.
13. Przybelski RJ, Daily EK, Kisicki JC, Mattia-Goldberg C, Bounds MJ, Colburn WA. Phase I study of the safety and pharmacologic effects of diaspirin crosslinked hemoglobin solution. Crit Care Med 1996;24:1993-2000.
14. Carmichael FJ, Ali AC, Campbell JA, Langlois SF, Biro GP, Willan AR, et al. A phase I study of oxidized raffinose crosslinked human hemoglobin. Crit Care Med 2000;28:2283-92.
15. Savitsky JP, Doczi J, Black J, Arnold JD. A clinical safety trial of stroma-free hemoglobin. Clin Pharmacol Ther 1978;23:73-80.
16. Przybelski R, Kisicki J, Dailey E, Mattia-Goldberg C, Bounds MJ, Colburn WA, et al. Diaspirin cross-linked hemoglobin (DCLHb): Phase I clinical safety assessment in normal healthy volunteers (abstract). Crit Care Med 1994;22:231.
17. Noone RBJ, Mythen MG, Vaslef SN. Effect of αα-cross-linked hemoglobin and pyridoxalated hemoglobin polyoxyethylene conjugate solutions on gastrointestinal regional perfusion in hemorrhagic shock. J Trauma 1998;45:457-69.
18. Conover CD, Lejeune L, Shum K, Shorr RG. The influence of polyethylene glycol conjugation on bovine hemoglobin's intrinsic effects on the gastrointestinal system of the rat. Life Sci 1996;59:1861-9.
19. Winslow RM, αα-crosslinked hemoglobin: was failure predicted by preclinical testing¿ Vox Sang 2000;79:1-20.
20. Saxena R, Wijnhoud AD, Carton H, Hacke W, Kaste M, Przybelski RJ, et al. Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. Stroke 1999;30:993-6.
21. Sloan EP, Koenigsberg M, Gens D, Cipolle M, Runge J, Mallory MN, et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock. A randomized controlled efficacy trial. JAMA 1999;282:1857-64.
22. Abassi Z, Kotob S, Pieruzzi F, Abouassali M, Keiser HR, Fratantoni JC, et al. Effects of polymerization on the hypertensive action of diaspirin cross-linked hemoglobin in rats. J Lab Clin Med 1997;129:603-10.
23. Rattan S, Rosenthal GJ, Chakder S. Human recombinant hemoglobin (rHb1.1) inhibits nonadrenergic noncholinergic (NANC) nerve-mediated relaxation of internal anal sphincter. J Pharmacol Exp Ther 1995;272:1211-6.
24. von Dobschuetz E, Hoffman T, Engelschalk C, Messmer K. Effect of diaspirin cross-linked hemoglobin on normal and postischemic microcirculation of the rat pancreas. Am J Physiol (Gastrointestinal and Liver Physiology). 1999;276:G1507-G14.
25. Moncada S, Palmer R, Higgs E. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-42.
26. Doherty DH, Doyle MP, Curry SR, Vali RJ, Fattor TJ, Olson JS, et al. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat Biotechnol 1998;16:672-6.
27. Matheson B, Kwansa H, Bucci E, Rebel A, Koehler R. Appearance of dissociable and cross-linked hemoglobins in the renal hilar lymph. J Lab Clin Med 2000;135:464.
28. Kuchan M, Frangos J. Shear stress regulates endothelin-1 release via protein kinase C and cGMP in cultured endothelial cells. Am J Physiol 1993;264:H150-H6.